New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareHGH Fragment 176-191 vs FOXO4-DRI

HGH Fragment 176-191 vs FOXO4-DRI

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
HGH Fragment 176-191
Anti-Aging & Longevity
FOXO4-DRI
Summary
HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
Half-Life
~30 minutes
Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
Admin Route
SubQ
Subcutaneous, Intraperitoneal (research)
Research
Typical Dose
250–500 mcg
5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
Frequency
1–3 times daily
3 consecutive days per cycle
Key Benefits
  • Selective fat burning without anabolic side effects
  • Reduces visceral and subcutaneous fat
  • No insulin resistance or blood glucose disruption
  • Does not stimulate IGF-1
  • May support cartilage and bone repair (at higher doses)
  • No effect on growth or organ size
  • Selectively clears senescent cells (senolytics)
  • Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
  • Demonstrated restoration of physical fitness in aged mice
  • May improve healthspan and reduce age-related tissue dysfunction
  • Potential for treatment of age-related pathologies driven by cellular senescence
  • Does not affect healthy non-senescent cells at therapeutic doses
Side Effects
  • Injection site irritation
  • Temporary lethargy
  • Headache (rare)
  • Nausea (rare)
  • Limited human data; largely preclinical evidence
  • Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
  • Weight loss observed at high doses in rodent studies
  • Unknown long-term safety profile in humans
Stacks With